Eli Lilly’s experimental triple-agonist retatrutide produced some of the largest weight-loss results reported in late-stage obesity trials, with high-dose arms showing average reductions near the high 20s percent range at planned readouts. The Phase 3 data presented by Lilly showed substantial mean weight loss and related improvements such as reduced knee pain in osteoarthritis cohorts. The results also included elevated discontinuation rates and novel skin-related adverse events in some arms, prompting discussion about tolerability and patient selection. Sponsors and clinicians noted the efficacy bar for future obesity drugs has risen; regulators and payers will weigh benefit–risk and long-term safety data as programs progress.